Exosomal miRNAs as a biomarker for early targeted therapy response in advanced triple negative breast cancer Ghent University
Triple negative breast cancer (TNBC) is a heterogeneous breast cancer subtype with limited
treatment options and poor prognosis following progression after neoadjuvant chemotherapy.
Transcriptional miRNA signatures of activation of MEK and PI3K pathways are highly prevalent in
TNBC and targeted therapies (TT) to modulate both pathways are in clinical trial. The current
challenge in clinical practice is learning to use the ...